Physician profile
Jillian E Gladd
NPI 1023456449
$7,535.70
in general payments reported to CMS, 2019-2025
23 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,442 · 2022: $1,292 · 2023: $1,445 · 2024: $1,057 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,522 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,522.05 |
| Education | $279.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $951.49 | 2021-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $913.79 | 2021-2025 | |
| Amgen INC. | $725.51 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $707.05 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Novartis Pharmaceuticals Corporation | $492.28 | 2021-2025 | |
| Ucb, INC. | $484.52 | 2021-2025 | Cimzia, Bimzelx |
| Incyte Corporation | $424.28 | 2021-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $407.88 | 2021-2023 | Winlevi, Blu-U, Odomzo |
| Pfizer INC. | $407.38 | 2021-2024 | |
| Journey Medical Corporation | $397.39 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $372.94 | 2021-2025 | Dupixent |
| Genzyme Corporation | $371.35 | 2021-2025 | |
| Lilly USA, LLC | $206.70 | 2021-2024 | Olumiant, Taltz, Ebglyss |
| Dermavant Sciences, INC. | $110.88 | 2023-2024 | Vtama |
| Biofrontera INC. | $96.44 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $93.46 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $90.33 | 2021-2023 | Adbry |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Epi Health, LLC | $66.34 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.70 | 2021 | |
| Vyne Pharmaceuticals INC. | $39.92 | 2021 | |
| Arcutis Biotherapeutics, INC. | $36.76 | 2023-2024 | Zoryve |
| Genentech USA, INC. | $24.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Gladd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.